AVITA Medical Inc (RCEL)

NASD · Healthcare · Medical Devices · USA

AVITA Medical Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

AVITA Medical develops cell-based and complementary products for acute wound management, including burns, traumatic injuries, and surgical repairs. Its core offering is RECELL, an autologous cell harvesting device that creates a skin cell suspension for wound treatment. The company also distributes PermeaDerm and Cohealyx. It serves burn centers, trauma facilities, and surgical settings primarily in the United States.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the AVITA Medical Inc stock.

Our verdict on RCEL

Overvalued: intrinsic value $3.60 per share, market price $15.77, margin of safety -337.7% (as of 2026-11-17).

A 0.9x revenue multiple, discounted for its losses, values the shares at $3.60; the price of $15.77 is 338% above that value.

ETFs with the most weight in RCEL

1 more funds hold it; the full list is part of the paid plan.

More on RCEL

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than RCEL in Medical Devices

48 more in this industry show a wider margin of safety.

Is RCEL undervalued or overvalued?

RCEL is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $3.60; the price of $15.77 is 338% above that value.

What is the intrinsic value of RCEL?

$3.60 per share (as of the 2026-11-17 close), against a market price of $15.77. That is a margin of safety of -337.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.